Insmed (INSM) Interest & Investment Income (2010 - 2026)
Insmed (INSM) posted quarterly Interest & Investment Income of $12.0 million for Q1 2026, down 13.42% year-over-year from $13.9 million in Q1 2025, and down 20.98% quarter-over-quarter from $15.2 million in Q4 2025.
Insmed (INSM) Interest & Investment Income (2010 - 2026) Analysis & Trends
Insmed's Interest & Investment Income history runs 17 years deep, the most recent figure standing at $12.0 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 13.42% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $58.8 million (up 0.62% YoY), while the FY2025 annual figure was $60.7 million, up 13.79% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $12.0 million, down from $15.2 million in the prior quarter.
- The five-year high for Interest & Investment Income was $18.3 million in Q3 2025, with the low at $137000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $10.6 million (2023), against an average of $10.5 million.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income surged 13536.07% in 2022, then fell 16.54% in 2024.
- Insmed's Interest & Investment Income stood at $8.3 million in 2022, then rose by 18.45% to $9.9 million in 2023, then jumped by 75.14% to $17.3 million in 2024, then retreated by 11.71% to $15.2 million in 2025, then decreased by 20.98% to $12.0 million in 2026.
- Business Quant data shows INSM's Interest & Investment Income at $12.0 million in Q1 2026, $15.2 million in Q4 2025, and $18.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | 36.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.98 Mn |
| Mar 31, 2026 | 12.04 Mn |
| Dec 31, 2025 | 15.24 Mn |
| Sep 30, 2025 | 18.29 Mn |
| Jun 30, 2025 | 13.23 Mn |
| Mar 31, 2025 | 13.91 Mn |
| Dec 31, 2024 | 17.26 Mn |
| Sep 30, 2024 | 16.98 Mn |
| Jun 30, 2024 | 10.29 Mn |
| Mar 31, 2024 | 8.78 Mn |
| Dec 31, 2023 | 9.85 Mn |
| Sep 30, 2023 | 10.58 Mn |
| Jun 30, 2023 | 11.17 Mn |
| Mar 31, 2023 | 10.52 Mn |
| Dec 31, 2022 | 8.32 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 835,000.00 |
| Mar 31, 2022 | 137,000.00 |
| Dec 31, 2021 | 61,000.00 |
| Sep 30, 2021 | 46,000.00 |